早期应用盐酸替罗非班在介入治疗的非ST段抬高型急性冠状动脉综合征患者中应用及效果  

The Application and Effect of Tirofiban Hydrochloride in Early Phase of Non-ST Elevation Acute Coronary Syndrome Intervention Treatment

作　　者：李文静[1] 

机构地区：[1]深圳市第二人民医院心内科,广东深圳518000

出　　处：《医学综述》2014年第1期190-192,共3页Medical Recapitulate

摘　　要：目的探讨早期应用盐酸替罗非班在介入治疗的非ST段抬高型急性冠状动脉综合征患者中应用效果。方法选取深圳市第二人民医院心内科2010年1月至2013年1月收治的98例非ST段抬高型急性冠状动脉综合征患者为研究对象,应用随机数字表法将患者分为维拉帕米组和替罗非班组,分别经冠状动脉内注入200μg维拉帕米和10μg/kg替罗非班,比较两组患者临床疗效和安全性。结果替罗非班组患者注射该药后首次及经皮冠状动脉腔内成形术结束前末次冠状动脉造影的TIMI血流分级3级获得率分别为81.63%和91.84%,显著高于维拉帕米组的57.14%和73.47%,两组比较差异有统计学意义(Z=8.118,Z=6.000,P<0.05),3 d后,替罗非班组患者血浆C反应蛋白、血清肌酸激酶同工酶和心肌肌钙蛋白I水平显著低于维拉帕米组[(4.3±1.8)mg/L vs(2.1±1.3)mg/L、(693.8±315.2)ng/L vs(272.7±254.3)ng/L、(82.7±11.3)ng/L vs(52.1±10.4)ng/L,P<0.05];维拉帕米组和替罗非班组患者主要心血管事件和出血发生率的差异无统计学意义[(6.12%vs 4.08%)、(6.12%vs 4.08%),P>0.05]。结论早期应用盐酸替罗非班在介入治疗的非ST段抬高型急性冠状动脉综合征患者中临床疗效确切,具有安全高效和不良反应少等特点。Objective To investigate the application effects of tirofiban hydrochloride in early phase of non-ST elevation acute coronary syndrome intervention treatment. Methods Ninety-eight non-ST elevation acute coronary syndrome patients who were treated in the Department of Cardiology in Sbenzhen Second Peo- ple＇s Hospital from Jan. 2010 to Jan. 2013 were chosen as the research objects. They were divided into vera- pamil group and tirofiban .hydrochloride group by random number table, who were injected 200 μg verapamil or 10 μg/kg tirofiban hydrochloride in coronary artery, respectively. The clinical efficacy and safety were eval- uated. Results The flow grade 3 class of TIMI rate the first time after injection of the drug and the last time before the end of percutaneous coronary angioplasty cavity were 81.63% and 91.84% in tirofiban hydrochlo- ride group, significantly higher than 57.14% and 73.47% of verapamil group, （ Z = 8.118, Z = 6. 000, P 〈 0.05 ） ,respectively. Plasma C-reactive protein, serum creatine kinase isoenzyme and cardiac troponin 1 in tirofiban hydrochloride group were significantly lower than that in verapamil group [ （4.3 ± 1.8 ） mg/L vs （2.1 ±1.3） mg/L,（693.8 ±315.2） ng/L vs（272.7 ±254.3） ng/L, （82.7 ±11.3） ng/L vs（52.1 ± 10.4） ng/L, （P 〈0.05 ）] after 3 days. There was no statistically significant difference in the incidence of major cardiovascular events and bleeding between the verapamil group and tirofiban hydroehioride group [（6.12% vs4.08%）,（6.12% vs4.08%）,P〉0.05].Conclusion Theapplieationeffeetsoftirofiban hydrochloride in early phase of non-ST elevation acute coronary syndrome intervention treatmentare sure, fea- tured with safe and effective, and less adverse reactions.

关 键 词：盐酸替罗非班 非ST段抬高型 急性冠状动脉综合征 临床疗效 

分 类 号：R543[医药卫生—心血管疾病]